Tecemotide in unresectable stage III non-small cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses.

Authors
Mitchell, P
Thatcher, Nick
Socinski, M
Wasilewska-Tesluk, E
Horwood, K
Szczesna, A
Martín, C
Ragulin, Y
Zukin, M
Helwig, C
Affiliation
Olivia Newton-John Cancer and Wellness Centre, Austin Hospital, Melbourne, VIC, Australia
Issue Date
2015-02-26

Metadata
Show full item record
Abstract
Tecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary endpoint but reported notable survival benefit with tecemotide versus placebo in an exploratory analysis of the predefined patient subgroup treated with concurrent chemoradiotherapy. Here, we attempted to gain further insight into the effects of tecemotide in START.
Citation
Tecemotide in unresectable stage III non-small cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses. 2015: Ann Oncol
Journal
Annals of Oncology
URI
http://hdl.handle.net/10541/346885
DOI
10.1093/annonc/mdv104
PubMed ID
25722382
Type
Article
Language
en
ISSN
1569-8041
Collections